ZVA Stock Chart & Stats
€2.87
€0.01(0.40%)
At close: 4:00 PM EDT
€2.87
€0.01(0.40%)
Day’s Range― - ―
52-Week Range€2.26 - €4.65
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€203.96M
Enterprise Value€205.35
Total Cash (Recent Filing)€166.85M
Total Debt (Recent Filing)€84.57M
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Nov 09, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding72,325,455
10 Day Avg. Volume0
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.74
Revenue Forecast (FY)€53.39M
Bulls Say, Bears Say
Bulls Say
Allogeneic Cell-therapy PlatformAn allogeneic, off-the-shelf approach could improve scalability and availability versus individualized cell therapies. The platform’s value depends on clinical validation, but it gives Cellectis a focused technology base for multiple cancer candidates.
Healthy Gross Margin ProfileThe high gross margin indicates that the underlying technology and partner-related activities can carry substantial value relative to direct costs. If revenue scales, this structure could support improved operating leverage, although current fixed costs remain too high.
Partnering And Licensing OptionalityA collaboration-led model can provide multiple monetization routes without relying solely on product sales. Upfronts, milestones, services and potential royalties may diversify future funding sources as programs advance, subject to partner execution and development success.
Bears Say
Declining And Volatile RevenueRevenue contraction after a strong prior year shows that Cellectis lacks a stable, predictable commercial revenue base. Volatility makes planning and funding more difficult and increases dependence on collaboration timing, milestones and pipeline progress.
Persistent Operating LossesCurrent revenue is insufficient to absorb the company’s operating cost base, leaving profitability dependent on successful clinical development and future partnering or commercialization. Sustained losses could require continued capital access and delay financial self-sufficiency.
Cash Burn And Weaker Balance SheetLarge recurring cash outflows increase the need for external financing, while higher leverage and a reduced equity cushion limit flexibility. This combination can constrain research investment and heighten dilution or refinancing risk if funding needs persist.
Cellectis SA News
ZVA FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was €2.26 and its highest was €4.65 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is €203.96M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Nov 09, 2026 which is in 60 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Aug 06, 2026. The company reported -€0.19 earnings per share for the quarter, beating the consensus estimate of -€0.227 by €0.037.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.18.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -€0.19 in its last earnings report, beating expectations of -€0.227. Following the earnings report the stock price went down -7.717%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in DE:ZVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.